The essential role of the Shh signaling pathway in ESCC cisplatin resistance in our studies and the limitation of an FDA-approved Shh inhibitor prompted us to identify a novel Shh inhibitor. The gene discussed is SHH; the disease is esophageal squamous cell carcinoma.